Faculty Opinions recommendation of Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.8286956.8718054 ◽

2011 ◽

Author(s):

Irene Litvan ◽

Rita Simoes

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Depressive Symptoms ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Pingchan granule for depressive symptoms in parkinson’s disease: A randomized, double-blind, placebo-controlled trial

Journal of Integrative Medicine ◽

10.1016/j.joim.2020.12.006 ◽

2020 ◽

Author(s):

Si-chun Gu ◽

Jie Zhou ◽

Qing Ye ◽

Can-xing Yuan

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Depressive Symptoms ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial

The Lancet Neurology ◽

10.1016/s1474-4422(10)70106-x ◽

2010 ◽

Vol 9 (6) ◽

pp. 573-580 ◽

Cited By ~ 277

Author(s):

Paolo Barone ◽

Werner Poewe ◽

Stefan Albrecht ◽

Catherine Debieuvre ◽

Dan Massey ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Depressive Symptoms ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.8638956.9139058 ◽

2011 ◽

Cited By ~ 1

Author(s):

John O'Brien ◽

John-Paul Taylor

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Dementia With Lewy Bodies ◽

Controlled Trial ◽

Lewy Bodies ◽

Parkinson’S Disease Dementia ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

P1-067: AMBROXOL AS PHARMACOLOGICAL CHAPERONE TARGETING GBA1 AS A DISEASE MODIFYING TREATMENT FOR PARKINSON'S DISEASE DEMENTIA: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Alzheimer s & Dementia ◽

10.1016/j.jalz.2018.06.069 ◽

2006 ◽

Vol 14 (7S_Part_5) ◽

pp. P296-P296

Author(s):

Stephen H. Pasternak ◽

Carolina Silveira ◽

Zhonghan Li ◽

Robert Bartha ◽

Michael Borrie ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Controlled Trial ◽

Phase 2 ◽

Parkinson’S Disease Dementia ◽

Double Blind ◽

Pharmacological Chaperone ◽

Double Blind Placebo ◽

Disease Modifying ◽

Disease Modifying Treatment

Download Full-text

Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial

Movement Disorders ◽

10.1002/mds.21226 ◽

2007 ◽

Vol 22 (2) ◽

pp. 179-186 ◽

Cited By ~ 185

Author(s):

Christopher G. Goetz ◽

Philippe Damier ◽

Christine Hicking ◽

Eugene Laska ◽

Thomas Müller ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients

Movement Disorders ◽

10.1002/mds.23954 ◽

2011 ◽

Vol 27 (1) ◽

pp. 106-112 ◽

Cited By ~ 66

Author(s):

Fabrizio Stocchi ◽

Rupam Borgohain ◽

Marco Onofrj ◽

Anthony H.V. Schapira ◽

Mohit Bhatt ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Early Parkinson’S Disease

Download Full-text

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

The Lancet ◽

10.1016/s0140-6736(17)31585-4 ◽

2017 ◽

Vol 390 (10103) ◽

pp. 1664-1675 ◽

Cited By ~ 244

Author(s):

Dilan Athauda ◽

Kate Maclagan ◽

Simon S Skene ◽

Martha Bajwa-Joseph ◽

Dawn Letchford ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Antidyskinetic properties of topiramate: a double-blind, placebo-controlled trial in patients with Parkinson's disease and levodopa-induced dyskinesias

http://isrctn.org/> ◽

10.1186/isrctn95151471 ◽

2013 ◽

Author(s):

Montague Silverdale

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial

Yearbook of Paediatric Endocrinology ◽

10.1530/ey.15.14.17 ◽

2018 ◽

Author(s):

Athauda D ◽

Maclagan K ◽

Skene SS ◽

Bajwa-Joseph M ◽

Letchford D ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

The effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression related to inflammation, insulin and lipid in patients with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial

Clinical Neurology and Neurosurgery ◽

10.1016/j.clineuro.2018.12.006 ◽

2019 ◽

Vol 176 ◽

pp. 116-121 ◽

Cited By ~ 6

Author(s):

Omid Reza Tamtaji ◽

Mohsen Taghizadeh ◽

Esmat Aghadavod ◽

Alireza Mafi ◽

Ehsan Dadgostar ◽

...

Keyword(s):

Gene Expression ◽

Parkinson’S Disease ◽

Fatty Acids ◽

Parkinson's Disease ◽

Vitamin E ◽

Controlled Trial ◽

Omega 3 Fatty Acids ◽

Omega 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text